10-Q: Cigna Group Reports Mixed Q3 Results Amidst Strategic Divestiture and Investment Impairment

The Cigna Group's third-quarter results show a decrease in net income, impacted by a significant investment impairment, while adjusted income from operations saw a modest increase.

Summary

• The Cigna Group reported a net income of $739 million for the third quarter of 2024, a decrease from $1.408 billion in the same period last year.
• Adjusted income from operations, which excludes certain items, was $2.112 billion, up from $2.011 billion in the prior year.
• The company's revenue increased to $63.694 billion, up from $49.048 billion year-over-year, driven by growth in pharmacy and other service revenues.
• A significant factor impacting net income was a $2.7 billion loss from the impairment of equity securities related to VillageMD.
• The company is in the process of selling its Medicare Advantage business to Health Care Service Corporation for approximately $3.3 billion in cash, expected to close in the first quarter of 2025.
• The effective tax rate increased to 30.8% for the quarter and 31.2% for the nine months ended September 30, 2024, primarily due to a valuation allowance on the tax benefit related to the impairment of equity securities.
• The company repurchased 8.8 million shares for approximately $2.4 billion during the quarter and 14.7 million shares for approximately $5.0 billion during the nine months ended September 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the significant impairment of the VillageMD investment and the decrease in net income, offset by positive revenue growth and adjusted income from operations. The strategic divestiture is a positive move, but the overall tone is cautious due to the financial impact of the impairment.

Positives

• Adjusted income from operations increased by 5% for the quarter and 8% for the nine months ended September 30, 2024.
• Total revenue increased by 30% for the quarter and 26% for the nine months ended September 30, 2024.
• Pharmacy revenues saw a substantial increase of 40% for the quarter and 35% for the nine months ended September 30, 2024.
• The company continues to make progress on its strategic divestiture of the Medicare Advantage business.
• The company has a strong share repurchase program, buying back 14.7 million shares for approximately $5.0 billion during the nine months ended September 30, 2024.

Negatives

• Net income decreased by 48% for the quarter and 51% for the nine months ended September 30, 2024.
• The company recorded a $2.7 billion loss due to the impairment of its investment in VillageMD.
• Net investment income decreased by 74% for the quarter and 21% for the nine months ended September 30, 2024.
• The effective tax rate increased to 30.8% for the quarter and 31.2% for the nine months ended September 30, 2024.

Risks

• The company faces risks related to the sale of its Medicare Advantage business, including regulatory approvals and closing conditions.
• The impairment of the VillageMD investment highlights the risk of losses from strategic investments.
• The company's financial performance is subject to market conditions, including interest rate and equity price risks.
• The company is exposed to risks related to its debt obligations and the potential for further indebtedness.
• The company is subject to regulatory risks, including changes in laws and regulations and uncertainties surrounding government-sponsored programs.

Future Outlook

The company expects to close the sale of its Medicare Advantage business in the first quarter of 2025 and intends to use the proceeds primarily for share repurchases. The company also expects continued volatility in private equity and real estate fund performance.

Management Comments

• Management believes that the vast majority of our investments will continue to perform under their contractual terms.
• Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate.
• Management believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability.

Industry Context

The results reflect the ongoing trends in the healthcare industry, including the increasing importance of pharmacy services and the challenges of managing medical costs. The strategic divestiture of the Medicare Advantage business is a significant move that aligns with the company's focus on its core businesses. The impairment of the VillageMD investment highlights the risks associated with healthcare investments and the need for careful due diligence.

Comparison to Industry Standards

• Cigna's revenue growth of 30% in the quarter is above the average for the health insurance industry, which has seen moderate growth due to increased healthcare spending.
• The medical care ratio of 82.8% is within the typical range for health insurers, but the increase of 230 bps indicates higher medical costs compared to the previous year.
• The impairment of the VillageMD investment is a significant event, and while not directly comparable to other companies, it highlights the risks associated with investments in healthcare providers, similar to challenges faced by other insurers with provider investments.
• Cigna's share repurchase program is a common practice among large health insurers, but the scale of the buyback is notable, indicating a strong focus on returning capital to shareholders.
• Compared to peers like UnitedHealth Group and Humana, Cigna's adjusted income from operations growth is moderate, reflecting the impact of the investment impairment.

Legal Proceedings

• The company is involved in ongoing litigation with Elevance regarding pricing and service claims, with a settlement reached on service-related claims and an appeal pending on pricing-related claims.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and the impairment of the VillageMD investment, but also by the share repurchase program.
• Customers may be impacted by changes in premiums and medical costs.
• Employees may be impacted by strategic changes and ongoing efficiencies.
• The sale of the Medicare Advantage business will impact customers and employees in that segment.

Next Steps

• The company will continue to work towards closing the sale of its Medicare Advantage business in the first quarter of 2025.
• The company will continue to monitor and evaluate the need for any additional valuation allowance on deferred tax assets.
• The company will continue to execute its share repurchase program.
• The company will continue to monitor the economic environment and its effect on its investment portfolio.

Key Dates

Keywords

Cigna, Healthcare, Pharmacy, Medicare Advantage, Investment Impairment, Financial Results, Share Repurchase, Evernorth Health Services, Medical Costs, Revenue Growth